Mesenchymal stromal cells: Tissue repair and immune modulation.
BM-derived mesenchymal stromal cells (MSC) differentiate along the mesenchymal lineage to bone, fat and cartilage. In vitro, MSC induce little, if any, proliferation of allogeneic lymphocytes. MSC inhibit the proliferation of activated T cells and the formation of cytotoxic T cells. In vivo, they appear to have anti-inflammatory effects. Preliminary studies suggest that MSC preferentially home to damaged tissue and therefore have therapeutic potential. Possible clinical indications include therapy-resistant severe acute GvHD, treatment of rejection of organ allografts and autoimmune disorders.
Le Blanc
K
K
Center for Allogeneic Stem Cell Transplantation, Department of Laboratory Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden. katarina.leblanc@medhs.ki.se
D001854:Bone Marrow Cells / Q000276:immunology; D006086:Graft vs Host Disease; D006680:HLA Antigens / Q000276:immunology; D007165:Immunosuppression Therapy; D059630:Mesenchymal Stem Cells / Q000276:immunology / Q000502:physiology*; D017154:Stromal Cells / Q000276:immunology / Q000502:physiology*; D014945:Wound Healing
D006680:HLA Antigens